Espin R, Medina-Jover F, Siguenza-Andrade J, Farran-Matas S, Mateo F, Figueras A
NAR Cancer. 2025; 7(1):zcaf007.
PMID: 40061566
PMC: 11886861.
DOI: 10.1093/narcan/zcaf007.
Ueda Y, Kiyonaka S, Selfors L, Inoue K, Harada H, Doura T
Nat Cell Biol. 2025; 27(3):530-543.
PMID: 39984655
DOI: 10.1038/s41556-025-01617-w.
Anand J, Droby G, Joseph S, Patel U, Zhang X, Klomp J
bioRxiv. 2025; .
PMID: 39975297
PMC: 11838190.
DOI: 10.1101/2025.01.26.634889.
Dong R, Wang J, Guan R, Sun J, Jin P, Shen J
Antioxidants (Basel). 2025; 14(1).
PMID: 39857438
PMC: 11760893.
DOI: 10.3390/antiox14010104.
Zhou Y, Lv J, Jin S, Fu C, Liu B, Shen Y
Front Pharmacol. 2025; 15():1526051.
PMID: 39850572
PMC: 11754881.
DOI: 10.3389/fphar.2024.1526051.
Increased c-MYC Expression Associated with Active IGH Locus Rearrangement: An Emerging Role for c-MYC in Chronic Lymphocytic Leukemia.
Guiyedi K, Parquet M, Aoufouchi S, Chauzeix J, Rizzo D, Al Jamal I
Cancers (Basel). 2024; 16(22).
PMID: 39594704
PMC: 11592262.
DOI: 10.3390/cancers16223749.
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
Yang Y, Badura M, OLeary P, Delavan H, Robinson T, Egusa E
Nat Cancer. 2024; 5(12):1885-1901.
PMID: 39558146
PMC: 11671220.
DOI: 10.1038/s43018-024-00848-4.
Excessive MYC-topoisome activity triggers acute DNA damage, MYC degradation, and replacement by a p53-topoisome.
Das S, Karmakar S, Venkatachalapathy H, Jha R, Batchelor E, Levens D
Mol Cell. 2024; 84(21):4059-4078.e10.
PMID: 39481385
PMC: 11560571.
DOI: 10.1016/j.molcel.2024.10.006.
Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability.
Igarashi T, Yano K, Endo S, Shiotani B
Cancers (Basel). 2024; 16(20).
PMID: 39456601
PMC: 11506635.
DOI: 10.3390/cancers16203507.
Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.
Yadav P, Bandyopadhyay A, Sarkar K
Discov Nano. 2024; 19(1):153.
PMID: 39292302
PMC: 11410751.
DOI: 10.1186/s11671-024-04104-7.
Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells.
Li P, Zhu X, Qu H, Han Z, Yao X, Wei Y
Onco Targets Ther. 2024; 17:741-753.
PMID: 39258222
PMC: 11385694.
DOI: 10.2147/OTT.S463217.
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer.
Meena J, Wang J, Neill N, Keough D, Putluri N, Katsonis P
Cancer Discov. 2024; 14(9):1699-1716.
PMID: 39193992
PMC: 11372365.
DOI: 10.1158/2159-8290.CD-22-0649.
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L
Signal Transduct Target Ther. 2024; 9(1):205.
PMID: 39164274
PMC: 11336233.
DOI: 10.1038/s41392-024-01907-z.
Oxidative cell death in cancer: mechanisms and therapeutic opportunities.
An X, Yu W, Liu J, Tang D, Yang L, Chen X
Cell Death Dis. 2024; 15(8):556.
PMID: 39090114
PMC: 11294602.
DOI: 10.1038/s41419-024-06939-5.
DNA-PKcs Inhibition Sensitizes Human Chondrosarcoma Cells to Carbon Ion Irradiation via Cell Cycle Arrest and Telomere Capping Disruption.
Lohberger B, Barna S, Glanzer D, Eck N, Leithner A, Georg D
Int J Mol Sci. 2024; 25(11).
PMID: 38892366
PMC: 11173223.
DOI: 10.3390/ijms25116179.
Impact of coconut kernel extract on carcinogen-induced skin cancer model: Oxidative stress, C-MYC proto-oncogene and tumor formation.
Sandhya S, Talukdar J, Gogoi G, Dey K, Das B, Baishya D
Heliyon. 2024; 10(8):e29385.
PMID: 38665592
PMC: 11043960.
DOI: 10.1016/j.heliyon.2024.e29385.
A guide to ferroptosis in cancer.
Yapici F, Bebber C, von Karstedt S
Mol Oncol. 2024; 18(6):1378-1396.
PMID: 38590214
PMC: 11161738.
DOI: 10.1002/1878-0261.13649.
Cell Immortality: Effective Techniques to Achieve and Investigate Its Applications and Challenges.
Chalak M, Hesaraki M, Mirbahari S, Yeganeh M, Abdi S, Rajabi S
Life (Basel). 2024; 14(3).
PMID: 38541741
PMC: 10971253.
DOI: 10.3390/life14030417.
Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability.
Ye M, Fang Y, Chen L, Song Z, Bao Q, Wang F
Nat Commun. 2024; 15(1):2377.
PMID: 38493213
PMC: 10944511.
DOI: 10.1038/s41467-024-46572-6.
Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer.
Al-Faze R, Ahmed H, El-Atawy M, Zagloul H, Alshammari E, Jaremko M
Biomed J. 2024; 48(1):100714.
PMID: 38452973
PMC: 11743316.
DOI: 10.1016/j.bj.2024.100714.